Board of Directors
Tim joined Horizon Pharma in June 2008 as president and chief executive officer and has served as chairman of our board of directors since 2010. Prior to joining Horizon Pharma plc, he served as president, chief executive officer and director of IDM Pharma, Inc., a public biopharmaceutical company which was acquired by Takeda America Holdings, Inc., or Takeda, in June 2009. Prior to IDM, Tim served as executive vice president, commercial operations at NeoPharm, Inc., a public biopharmaceutical company. From 2001 to 2005, he served as divisional vice president and general manager, immunology, where he led the global development and launch of the multi-indication biologic HUMIRA and divisional vice president, global cardiovascular strategy at Abbott, now AbbVie. From 1998 to 2001, Tim served as director, CELEBREX North America and arthritis team leader, Asia Pacific, Latin America and Canada at G.D. Searle & Company. From 1991 to 1998, he also held sales and marketing roles with increasing responsibility at G.D. Searle, Merck & Co., Inc. and Wyeth.
Tim received his Bachelor of Arts in Business from Muhlenberg College, in Allentown, Pa.. He serves as chairman of the board of Egalet Corporation (NASDAQ: EGLT) and the Illinois Biotechnology Innovation Organization (iBIO) and sits on the board of directors of Sucampo Pharmaceuticals, Inc. (NASDAQ: SCMP), the Biotechnology Innovation Organization (BIO), World Business Chicago (WBC) and the Greater Chicago Arthritis Foundation. He is also a member of the Illinois Innovation Council.
Michael has served on ther board of directors since September 2011 and as lead independent director of the company since August 2012. He is executive chairman of Amplyx Pharmaceuticals, Inc., chairman and chief executive officer of Reneo Pharmaceuticals, Inc. and a venture partner at Pappas Ventures. Michael most recently served as president and chief executive officer at Lumena Pharmaceuticals, which was acquired by Shire plc in June 2014. He has more than 40 years of experience in the pharmaceutical and biotechnology industries, and has held senior positions at a number of companies, including president and chief executive officer of SGX Pharmaceuticals, Inc. (sold to Eli Lilly in 2008), president and chief executive officer of Trega Biosciences, Inc. (sold to Lion Bioscience in 2001) and president of BioChem Therapeutic Inc. For approximately 20 years, Michael also serves on the board of directors of BioMarin Pharmaceutical Inc., Mirati Therapeutics, Inc., Amplyx Pharmaceuticals, Inc., Balance Therapeutics, Inc. and Biothera Pharmaceuticals, Inc.
Michael received a Bachelor of Science in Chemistry from the University of Nottingham in the United Kingdom.
Liam joined the board of directors in September 2014. Liam is a Chartered Director and Chartered Accountant, and was elected to the position of President of the Institute of Directors of Ireland in May 2013. In February 2015, he was appointed to the board of directors of Malin Corporation plc, a newly established Irish-based global life sciences company. Most recently, he was executive vice president and company secretary of Elan Corporation plc and served in that role from December 2001 until the merger of Elan with Perrigo in December 2013. He was previously an executive director of Elan between 2003 and 2007, having joined the organization as financial controller in 1994. He is also a former president of the Financial Executives’ Association of Ireland.
Liam graduated with a degree in commerce from the University College Dublin.
Dr. Himawan has served on the board of directors since July 2007. In 1999, he joined Essex Woodlands Health Ventures, L.P., a venture capital firm, where he now serves as a managing director. He also serves on the boards of directors of Catalyst Biosciences, Inc., MediciNova, Inc. and Light Sciences Oncology, Inc. Dr. Himawan co-founded Seed-One Ventures, a venture capital firm, where from 1996 to 1999 he served as a managing director. From 1983 to 1996, Dr. Himawan was a scientist in academic and industrial settings.
Dr. Himawan received his Bachelor of Science in Biology from the Massachusetts Institute of Technology and his doctorate in biological chemistry and molecular pharmacology from Harvard University.
Ron has served on the board of directors since September 2011. He is currently the chief financial officer of BioQ Pharma, Inc., a private specialty pharmaceutical company. Prior to that, Ron held senior positions at a number of biopharmaceutical companies, including chief financial officer at Sagent Pharmaceuticals, Inc. and NeoPharm, Inc. and corporate controller and interim chief financial officer at Abraxis BioScience, Inc. (formerly American Pharmaceutical Partners, Inc.). In addition, he previously served as corporate controller for Applied Power, Inc. and R.P. Scherer Corporation and held multiple finance positions at Kmart Corporation.
Ron received a Bachelor of Science in Accounting from Michigan State University and a master’s degree in finance from Walsh College.
Gino has served on the board of directors since March 2012. He currently serves as the chairman of the board of directors of AMAG Pharmaceuticals, Inc. and is onthe board of directors of Intercept Pharmaceuticals and Collegium Pharmaceuticals, and is retired from a distinguished career with Eli Lilly and Company that spanned nearly three decades. Gino previously served on the board of directors for Sorin SpA from 2012 to 2015, when it was acquired by LivaNova plc. He capped his career at Lilly as a member of the company’s executive committee and as the senior vice president of corporate strategy and business development.
Gino holds a degree in mechanical engineering from the University of Bologna and a Master of Business Administration from the University of Rochester.
Tom has served on the board of directors since April 2014. In his most recent role, he was director, president and chief executive officer of Human Genome Sciences (HGS) from 2004 to 2012 when HGS was acquired by GlaxoSmithKline. Before leading HGS, Tom spent nearly 20 years in senior roles at Abbott and its affiliates in the United States and Asia, most recently serving as the president of TAP Pharmaceutical Products, Inc., which was jointly owned by Abbott and Takeda Pharmaceutical Company, Inc. During his tenure, he led the growth of TAP from approximately $2 billion to more than $4 billion in annual revenue. Tom began his career in 1974 with Arthur Andersen & Co. From 1979 to 1985, he was a management consultant with McKinsey and Company, Inc., working with multinational companies in the United States, Europe and Japan.
Tom holds a bachelor’s degree from the College of William & Mary, and a Master of Business Administration from the University of Chicago Graduate School of Business. Currently, he is the chairman of the board of directors of Vanda Pharmaceuticals, Inc. He is also a member of the board of directors of the Biotechnology Innovation Organization (BIO) and a member of the board of visitors of the College of William & Mary.